Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
|Articles|October 4, 2012
InsideOutsourcing
Advertisement
Coming in December 2012
Reach thousands of the most influential decision makers in the pharmaceutical and biopharmaceutical industries!
Inside Outsourcing - a special annual issue on outsourcing strategies - is brought to you buy the editorial team of the most respected magazines serving the pharmaceutical and biopharmaceutical industries.
AD RESERVATION DEADLINE: NOVEMBER 7, 2012
Contact your sales representative to book a premium position today!
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.
Advertisement
Advertisement
Trending on PharmExec
1
The Most Important Lessons Learned from Building CGT Supply Chains: LogiPharma 2026
2
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
3
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
4
Viatris Acquires Pacira BioSciences for $1.65 Billion
5